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Myotonic dystrophy type 1 (DM1) is a multisystemic disorder with predominant myotonia
and muscular dystrophy which is caused by CTG-repeat expansions in the DMPK
gene. These repeat expansions are transcribed and the resulting mRNA accumulates
RNA-binding proteins involved in splicing, resulting in a general splicing defect. We
observed nuclear envelope (NE) alterations in DM1 primary myoblasts. These included
invaginations of the NE as well as an altered composition of the nuclear lamina.
Specifically, we investigated NE transmembrane proteins (NETs) in DM1 primary
myoblasts, staining to determine if their distribution was altered compared to controls
and if this could contribute to these structural defects. We also tested the expression
of these NETs in muscle and how localization changes in the DM1 primary myoblasts
undergoing differentiation in vitro to myotubes. We found no changes in the localization
of the tested NETs, but most tended to exhibit reduced expression with increasing
DMPK-repeat length. Nonetheless, the DM1 patient expression range was within the
expression range of the controls. Additionally, we found a down-regulation of the possible
nesprin 1 giant isoform in DM1 primarymyoblasts which could contribute to the increased
NE invaginations. Thus, nesprin 1 may be an interesting target for further investigation in
DM1 disease pathology.
Keywords: myotonic dystrophy type 1, nuclear envelope, nuclear envelope transmembrane proteins, myoblasts,
myotubes
INTRODUCTION
Myotonic dystrophies (DM) are caused by repeat expansions in non-coding regions of the DMPK
(type 1, DM1) and CNBP (type 2, DM2) genes. The transcribed, repeat-containing RNA forms
hairpin structures which yield a strong interaction with certain RNA binding proteins. Patient
cells accumulate foci containing this RNA and its interacting proteins. Amongst these interacting
proteins are MBNL-proteins, which are involved in the regulation of alternative splicing. The
accumulation of these proteins on the repeat RNA leads to them not being available for normal
splicing so that a general mis-splicing (“spliceopathy”) appears to occur with a shift to embryonic
splice variants.
Clinically, DM is a progressive multisystemic disorder characterized by myotonia, muscle
weakness, cataracts, and cardiac arrhythmia that can evolve to cardiomyopathy, insulin
insensitivity and diabetes, testicular failure, and hypogammaglobulinemia (Udd and Krahe, 2012;
Wenninger et al., 2018). The predominant muscle involvement brands DM as the most frequent
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muscular dystrophy in adulthood. Expansions of a CTG repeat
in the 3’ UTR of the DMPK gene cause DM1 (Fu et al., 1992).
Up to 35 of these CTG repeats are considered to be normal, 35 to
49 repeats are a premutation, and 50 or more CTG triplets are
considered to be disease causing. There is a rough correlation
between repeat tract length and disease severity in DM1. The
longer the CTG repeats the more severe the disease. Between
50 and ∼150 repeats have been observed in patients with mild
phenotype and∼100 to∼1000 repeats were identified in patients
with classical DM, while more than 1000 CTG-triplets result in
congenital DM, the most severe form of the disease (De Antonio
et al., 2016).
Muscle differentiation defects have been described for DM1
(Furling et al., 2001; Mastroyiannopoulos et al., 2008), but it
is unclear if the observed nuclear envelope alterations in DM1
myoblasts (Meinke et al., 2018) contribute to these defects in
a similar manner as they do to nuclear envelope linked disease
(Meinke and Schirmer, 2016). The most visible NE alterations
are invaginations, which have been previously observed in
DM1 fibroblasts (Rodriguez et al., 2015), and down-regulation
of the lamins A and B1 (Meinke et al., 2018). We found a
correlation between DMPK repeat length and the number of
nuclei with NE invaginations (Meinke et al., 2018). With the aim
to investigate which factors—apart from lamins—contribute to
these structures, we screened a set of selected NE transmembrane
proteins (NETs) for altered distribution in DM1 patients.
NETs have been linked to a wide range of disorders which
include several myopathies (Meinke and Schirmer, 2016). In the
light of the NE aberrations observed in DM1 myoblasts and
myotubes (Meinke et al., 2018), NETs are possible candidates
to contribute to DM1 muscle pathology. We decided to test
the proteins emerin, LBR, TMEM38a, TMEM70, SUN1, SUN2,
nesprin 1, and nesprin 2 for their localization and expression
in primary DM1 myoblasts compared to controls. All of these
proteins are NETs expressed inmuscle (Wilkie et al., 2011; Korfali
et al., 2012). Of these selected NETs, muscular dystrophies are
linked to emerin (Bione et al., 1994), nesprin 1 and nesprin
2 (Zhang et al., 2007), as well as SUN1 and SUN2 (Meinke
et al., 2014). SUN1, SUN2, nesprin 1, and nesprin 2 are all core
components of the LINC (linker of nucleo- and cytoskeleton)
complex (Crisp et al., 2006), while emerin is also involved in
connecting the nucleus to the cytoskeleton (Salpingidou et al.,
2007). The NETs Tmem38a and LBR are involved in genome
organization (Holmer and Worman, 2001; Robson et al., 2016).
Nesprins1 and 2 encompass several proteins due to having many
splicing isoforms, some of which are specifically up-regulated
during muscle differentiation (Duong et al., 2014).
Further indication for a possible NE involvement comes
from myotonic dystrophy protein kinase (DMPK), the protein
encoded by the DMPK gene, which has been reported to localize
to the NE. DMPK has been identified at the NE in HeLa cells
as well as in C2C12 mouse myoblasts and neonatal rat cardiac
myocytes (Harmon et al., 2008, 2011) and reduced DMPK levels
in DM1 patients have been observed (Fu et al., 1993). However,
if haploinsufficiency of DMPK is a relevant factor in DM1
pathology remains unclear as two different DMPK-knockout
mouse models show either a late onset progressive myopathy or




Primary humanmyoblasts were obtained from theMuscle Tissue
Culture Collection (MTCC) at the Friedrich-Baur-Institute
(Department of Neurology, Ludwig-Maximilians-University,
Munich, Germany). All control and patient materials were
obtained with written informed consent of the donor. Ethical
approval for this study was obtained from the ethical review
committee at the Ludwig-Maximilians-University, Munich,
Germany (reference 45–14). Repeat length was diagnosed on
DNA extracted from blood. DM1 patients had the following
DMPK repeat lengths: DM1-1 240-430; DM1-2 400-600; DM1-
3 1100-1300; DM1-4 1500. The patient cell lines used are
identical to those where a repeat-length depending enrichment
of nucleoplasmic reticuli was seen (Meinke et al., 2018).
Tissue Culture
Myoblasts were grown in tissue culture using skeletal muscle
cell growthmedium (PeloBiotech,Munich, Germany).Myoblasts
were kept from reaching confluency to avoid differentiation.
Passage numbers were matched for controls and patient cells for
the respective experiments, throughout all experiments passage
numbers 8 to 10 have been used. Coverslips for myoblast
immunohistochemistry were fixed at about 60–70 % confluence.
Cell lysates for Western blot were taken at the same confluence,
all at an average of 3 days of culturing after the last splitting. All
samples were taken at least two passages after thawing.
For differentiation confluent myoblasts were cultivated for 7
days in DMEM containing 5% horse serum.
Immunohistochemistry
Myoblasts were fixed with methanol (−20◦C). Primary
antibodies used for staining include: lamin A/C 4A7, emerin
5D10, nesprin 1 8C3 (provided by Glenn E. Morris), nesprin 1,
nesprin 2 (provided by Didier Hodzic), Sun1 Atlas (HPA008346),
Sun2 11208, LBR 11745, TMEM70 (provided by Eric C.
Schirmer) and TMEM38a Milipore (06-1005). All secondary
antibodies were Alexafluor conjugated. DNA was visualized with
DAPI (4,6-diamidino-2 phenylindole, dihydrochloride).
Microscopy and Image Analysis
All images were obtained using an Olympus FluoView
FV1000/BX 61microscope equipped with a 1.42 NA 60x
objective and 3x zoom magnification. Image analysis was
performed using ImageJ software.
Protein Extracts
Myoblasts were washed with 1x PBS and trypsinized. Cell
suspensions were inactivated with 10% FCS containing DMEM,
collected in 1.5ml tubes, centrifuged and washed twice in PBS.
Cell pellets were directly dissolved in 10mMTris/HCl pH 7.6 1 %
SDS lysis buffer containing protease inhibitors (cOmplete Tablets
EDTA-free Roche 04 693 132 001).
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For myotube extracts we first separated the myotubes using
a minimal trypsin treatment to detach myotubes that were then
gently centrifuged to sediment myotubes and separate them from
remaining mono-nucleated cells: after this we used the same
protocol as for myoblasts.
Western Blotting
Proteins from whole protein extracts were separated by SDS
gel electrophoresis using 4–15% TGX (BioRad #456-8087)
and self-prepared gels. Western blotting was performed using
the Trans-Blot R© TurboTM system (BioRad). Proteins were
transferred to low fluorescent PVDF membranes (part of Trans-
Blot R© TurboTM RTA Transfer Kit #170-4274). Membranes
were blocked with 5% BSA or 5% skim milk in 1xTBS/0.1%
Tween R©20. Primary antibodies used were: lamin A/C 4A7,
emerin 5D10, nesprin 1 8C3 (provided by Glenn E. Morris),
nesprin 1, nesprin 2 (provided by Didier Hodzic), Sun1 Atlas
(HPA008346), Sun2 11208, LBR 11745, TMEM70 (provided
by Eric C. Schirmer), and TMEM38a Millipore (06-1005).
As loading controls for quantification, mouse anti-GAPDH
(Milipore #MAB374), rabbit anti-GAPDH (Cell Signaling
D16H1; XP #5174) and goat anti-GAPDH (Thermo PA1-
9046) were used. Secondary antibodies used were: donkey
anti-mouse IRDye 680RD, donkey anti-mouse IRDye 800CW,
donkey anti-rabbit IRDye 680RD, donkey anti-rabbit IRDye
800 CW, and donkey anti-goat HRP (Dianova 705-035-003).
For chemiluminescence detection we used Weststar Supernova
(Cyanagene XLS3). All Western blot images were obtained using
a Licor FC. Quantification was done using the Licor ImageStudio
Software. Western blots were repeated at least twice to confirm
the results (Figure S1: complete blots).
RESULTS
First, we tested the expression levels of the NETs emerin,
LBR, SUN2, TMEM70, and TMEM38a in four DM1 patient-
derived primary myoblasts of different DMPK repeat length and
compared them to four controls (Figure 1A).
The range of emerin expression levels within the set of
patient-derived myoblasts is no greater than the expression range
of the controls. This is also the case for LBR (Figure 1A).
However, for SUN2 expression decreased with increasing repeat
length. Nonetheless, compared to controls these changes seem
to be within the normal expression range for SUN2. The same
tendency can be observed for TMEM70; also here the expression
is within the control range. For TMEM38a we see a tendency for
the ∼35 kDa band to increase with increasing repeat length, but
also without deviation from the control range.
The immunofluorescence stainings for these NETs show,
similar to the Western blots, no big differences between patients
and controls in their localization (Figure 1B). Emerin, LBR,
SUN2, and SUN1 antibodies stained the NE in both patients
and controls. In addition, NE invaginations were stained by
these four proteins in the patient samples. For TMEM38a and
TMEM70 we did not observe NE staining in either patient
or control myoblasts, consistent with their induction and NE
localization occurring during myogenesis (data not shown). The
only difference is that in the controls lines we see spots within the
nucleus stained by the TMEM38a antibody. These spots seem to
be reduced in patient cells (Figure 1B).
Due to the fact that some nesprin isoforms are up-
regulated during muscle differentiation (Duong et al., 2014),
we decided to test the expression of the nesprins in both
myoblasts and myotubes of patients and controls (Figure 2).
There are two skeletal muscle specific isoforms of nesprin 1
and 2, nesprin-1-alpha-2 (N1-α2, ∼111 kDa) and nesprin-2-
alpha-1 (N2-α1, ∼72 kDa). Other detected bands are likely
degradation products (Duong et al., 2014). For nesprin 1,
we used two different antibodies: N1-α2 polyclonal and 8C3
monoclonal. In myoblasts both antibodies detect the possible
giant isoform (300+ kDa) and the N1-α2 antibody detects
in addition the muscle-specific 111 kDa band. The 8C3
antibody shows that nesprin1 giant is down-regulated in the
DM1 patients and the N1-α2 antibody shows a similar result
for the possible giant isoform, although not as clearly. In
myotubes several additional bands are detected, but all are
comparable to controls. However, there is a tendency for
decreased expression of these isoforms with increased repeat
length. Immunofluorescence staining with the N1-α2 antibody
shows no obvious differences between controls and patients
(Figure 2A).
For nesprin 2 we did not detect any expression changes
between controls and patients in the myoblasts, but in myotubes
there is also the tendency of a ∼250 kDa band to decrease with
increasing repeat length in the patients; however, as observed
with the other proteins, this decrease is still within the range
observed in controls. Immunofluorescence staining shows a
weaker NE staining compared to nesprin 1 but no differences
between controls and patients (Figure 2B).
DISCUSSION
Based on our prior observation of NE alterations in DM1
myoblasts (Meinke et al., 2018), we investigated NETs regarding
their expression and localization to explore their possible
contribution to these structural changes. In myoblasts we found
no localization changes for any of the investigated NETs (emerin,
LBR, SUN1, SUN2, TMEM38a, TMEM70, nesprin 1, and nesprin
2). However, this does not exclude a contribution of the NE in
DM1. A study of NETs in Emery-Dreifuss muscular dystrophy
(EDMD) primary myoblasts showed that NETs are inconsistent
markers for this disease (Le Thanh et al., 2017) despite the fact
that all identified EDMD causing mutations are in NE proteins.
The missing NE staining of TMEM38a in myoblasts as well as
the observed speckles inside the nucleus are consistent with other
published data, although the NE localization could be confirmed
in muscle fibers (Le Thanh et al., 2017). The same is probably the
case for TMEM70. The observed tendency of reduced expression
with increasing repeat length within the patients for SUN2,
TMEM70 and to some degree as well emerin and the ∼30 kDa
band detected by the TMEM38a antibody might reflect the fact
that not all DM1 myoblast nuclei have invaginations. Therefore,
this might reflect changes in a subpopulation of cultured cells.
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FIGURE 1 | Expression and localization of nesprin1 and nesprin2 primary myoblasts and myotubes. Western Blot, quantification and immunofluorescence staining of
primary control and DM1 myoblasts and myotubes for nesprin1 (A) and nesprin2 (B). DM1 samples are ordered according their diagnosed repeat length from left
(small repeat) to right (long repeat). Scale bar 10µm. The lanes for DM1-3 and DM1-4 have been rearranged for the nesprin1 blots to allow a presentation according
to repeat length (indicated by black boxes). For original blots see supplemental material.
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FIGURE 2 | Expression and localization of different nuclear envelope proteins in myoblasts. (A) Western Blot and quantification of primary control and DM1 myoblasts
for emerin, LBR, Sun2 TMEM70, and TMEM38a. DM1 samples are ordered according their diagnosed repeat length from left (small repeat) to right (long repeat). The
lanes for DM1-3 and DM1-4 have been rearranged for the LBR, SUN2, TMEM70, and TMEM38a blots to allow a presentation according to repeat length (indicated by
black boxes). For original blots see supplemental material. (B) Immunofluorescence staining of primary control and DM1 myoblasts for emerin, LBR, Sun2 TMEM38a
TMEM70 and Sun1. Scale bar 10µm.
Frontiers in Physiology | www.frontiersin.org 5 October 2018 | Volume 9 | Article 1532
Hintze et al. NETs in DM1
The decreased expression of nesprin 1 giant in DM1myoblasts
might be a contributory factor for the NE invaginations as
nesprins are thought to form a network around the nucleus,
thus contributing to its stability (Lu et al., 2012). However,
it will be necessary to undertake further investigations to
confirm this. The expression of smaller nesprin 1 and 2
isoforms during differentiation shows a similar tendency as
the expression of the NETs SUN2, TMEM70, emerin and
the possible TMEM38a isoform: reduced expression with
increasing repeat length while still being in the range of the
controls.
Overall the accumulation of small expression changes in
several NETs could have an effect on NE mechanical stability,
resulting in the NE invaginations observed in the patient cells.
The expression changes observed for the nesprin 1 giant isoform
could be contributory not only to the NE deformations but also to
the disease phenotype, consistent with reported NE aberrations
from nesprin 1 mutations linked to EDMD (Zhang et al., 2007)
and spinocerebellar ataxia (Gros-Louis et al., 2007).
CONCLUSION
Changes in NET expression levels may contribute to NE
alterations observed in DM1 primary myoblasts. Several
muscle NETs showed expression changes which appear to
correlate with DMPK-repeat length. The giant isoform of
nesprin 1 seems to be a good candidate for further analysis
regarding its potential contribution to DM1 NE alterations and
pathology.
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